Clopidogrel Acino

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

klopidogrel

Available from:

Acino AG

ATC code:

B01AC04

INN (International Name):

clopidogrel

Therapeutic group:

Antitrombotična sredstva

Therapeutic area:

Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke

Therapeutic indications:

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA), ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy, Patients suffering from acute coronary syndrome. , ,.

Product summary:

Revision: 6

Authorization status:

Umaknjeno

Authorization date:

2009-07-28

Patient Information leaflet

                                23
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalnem pretisnem omotu za zagotovitev zaščite pred
vlago.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Acino AG
Am Windfeld 35
84714 Miesbach
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/09/532/001 – 007
13.
ŠTEVILKA SERIJE
Serija
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Klopidogrel Acino 75 mg
Zdravilo nima več dovoljenja za promet
24
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
Klopidogrel Acino 75 mg filmsko obložene tablete
Klopidogrel
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Acino AG
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Serija
5.
DRUGI PODATKI
Zdravilo nima več dovoljenja za promet
25
B. NAVODILO ZA UPORABO
Zdravilo nima več dovoljenja za promet
26
NAVODILO ZA UPORABO
KLOPIDOGREL ACINO 75 MG FILMSKO OBLOŽENE TABLETE
Klopidogrel
PRED ZAČETKOM JEMANJA NATANČNO PREBERITE NAVODILO, KER VSEBUJE ZA
VAS POMEMBNE PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne vašim.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali farmacevtom. Posvetujte
se tudi, če opazite katere koli neželene učinke, ki niso navedeni v
tem navodilu. Glejte
poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo Klopidogrel Acino in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Acino
3.
Kako jemati zdravilo Klopidogrel Acino
4.
Možni neželeni učinki
5.
Shranjevanje zdravila Klopidogrel Acino
6.
Vsebina pakiranja in dodatne informacij
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima več dovoljenja za promet
2
1.
IME ZDRAVILA
Klopidogrel Acino 75 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki
klopidogrelijevega besilata.
Pomožne snovi z znanim učinkom
Ena filmsko obložena tableta vsebuje 3,80 mg hidrogeniranega
ricinusovega olja.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Bele do belkaste, marmorirane, okrogle, bikonveksne filmsko obložene
tablete.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Klopidogrel je indiciran pri odraslih za preprečevanje
aterotrombotičnih dogodkov pri:

bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni),
ishemično kapjo (od
7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko
boleznijo.

bolnikih z akutnim koronarnim sindromom:
-
akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina
ali miokardni
infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen
stent po perkutani
koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA
– acetylsalicylic acid).
-
akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA
pri bolnikih, ki se
zdravijo z zdravili in so primerni za trombolitično zdravljenje.
_Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri
atrijski fibrilaciji _
Pri odraslih bolnikih z atrijsko fibrilacijo, ki imajo vsaj en
dejavnik tveganja za žilne dogodke in ki
niso primerni za zdravljenje z antagonisti vitamina K (VKA) ter imajo
majhno tveganje za krvavitev,
je klopidogrel v kombinaciji z ASA indiciran za preprečevanje
aterotrombotičnih in trombemboličnih
dogodkov, vključno z možgansko kapjo.
Za dodatne informacije glejte poglavje 5.1.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje

Odrasli in starostniki
Klopidogrel se mora dajati kot enkratni dnevni odmerek 75 mg.
Pri bolnikih z akutnim koronarnim sindromom:
–
Akutni koronarni sin
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-08-2016
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-08-2016
Public Assessment Report Public Assessment Report Bulgarian 15-04-2016
Patient Information leaflet Patient Information leaflet Spanish 11-08-2016
Public Assessment Report Public Assessment Report Spanish 15-04-2016
Patient Information leaflet Patient Information leaflet Czech 11-08-2016
Public Assessment Report Public Assessment Report Czech 15-04-2016
Patient Information leaflet Patient Information leaflet Danish 11-08-2016
Public Assessment Report Public Assessment Report Danish 15-04-2016
Patient Information leaflet Patient Information leaflet German 11-08-2016
Public Assessment Report Public Assessment Report German 15-04-2016
Patient Information leaflet Patient Information leaflet Estonian 11-08-2016
Public Assessment Report Public Assessment Report Estonian 15-04-2016
Patient Information leaflet Patient Information leaflet Greek 11-08-2016
Public Assessment Report Public Assessment Report Greek 15-04-2016
Patient Information leaflet Patient Information leaflet English 11-08-2016
Public Assessment Report Public Assessment Report English 15-04-2016
Patient Information leaflet Patient Information leaflet French 11-08-2016
Public Assessment Report Public Assessment Report French 15-04-2016
Patient Information leaflet Patient Information leaflet Italian 11-08-2016
Public Assessment Report Public Assessment Report Italian 15-04-2016
Patient Information leaflet Patient Information leaflet Latvian 11-08-2016
Public Assessment Report Public Assessment Report Latvian 15-04-2016
Patient Information leaflet Patient Information leaflet Lithuanian 11-08-2016
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-08-2016
Public Assessment Report Public Assessment Report Lithuanian 15-04-2016
Patient Information leaflet Patient Information leaflet Hungarian 11-08-2016
Summary of Product characteristics Summary of Product characteristics Hungarian 11-08-2016
Public Assessment Report Public Assessment Report Hungarian 15-04-2016
Patient Information leaflet Patient Information leaflet Maltese 11-08-2016
Public Assessment Report Public Assessment Report Maltese 15-04-2016
Patient Information leaflet Patient Information leaflet Dutch 11-08-2016
Public Assessment Report Public Assessment Report Dutch 15-04-2016
Patient Information leaflet Patient Information leaflet Polish 11-08-2016
Public Assessment Report Public Assessment Report Polish 15-04-2016
Patient Information leaflet Patient Information leaflet Portuguese 11-08-2016
Summary of Product characteristics Summary of Product characteristics Portuguese 11-08-2016
Public Assessment Report Public Assessment Report Portuguese 15-04-2016
Patient Information leaflet Patient Information leaflet Romanian 11-08-2016
Public Assessment Report Public Assessment Report Romanian 15-04-2016
Patient Information leaflet Patient Information leaflet Slovak 11-08-2016
Public Assessment Report Public Assessment Report Slovak 15-04-2016
Patient Information leaflet Patient Information leaflet Finnish 11-08-2016
Public Assessment Report Public Assessment Report Finnish 15-04-2016
Patient Information leaflet Patient Information leaflet Swedish 11-08-2016
Public Assessment Report Public Assessment Report Swedish 15-04-2016
Patient Information leaflet Patient Information leaflet Norwegian 11-08-2016
Summary of Product characteristics Summary of Product characteristics Norwegian 11-08-2016
Patient Information leaflet Patient Information leaflet Icelandic 11-08-2016
Summary of Product characteristics Summary of Product characteristics Icelandic 11-08-2016
Patient Information leaflet Patient Information leaflet Croatian 11-08-2016
Public Assessment Report Public Assessment Report Croatian 15-04-2016

Search alerts related to this product